Back
CE / CME
Integrating Genotype Into Counseling and Management Planning in Pediatric Sensorineural Hearing Loss: The Role of Genetic Counselors
Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit
Physicians: maximum of 0.50 AMA PRA Category 1 Credit™
Nurse Practitioners/Nurses: 0.50 Nursing contact hour
Genetic Counselors: 0.50 CEUs or 0.50 Category 1 Contact Hour
Released: July 13, 2026
Expiration: July 12, 2027
Activity
Genetic Testing in Pediatric SNHL
Genetic testing is now central to the etiologic evaluation of pediatric SNHL. For genetic counselors, the clinical value of genetic testing extends beyond simply identifying a molecular diagnosis. A confirmed genotype also can inform recurrence risk, prognosis, surveillance strategies, family communication, and discussions about approved and emerging interventions like cochlear implant or gene therapy.1
In this module, I discuss the integration of genetic testing results into counseling and management planning for pediatric SNHL where there is a confirmed pathogenic diagnosis of genetic hearing loss. Through practical patient case examples, we will practice identifying implications, distinguishing actionable findings from uncertainty, and communicating intervention and surveillance recommendations to families through a patient-centered care approach.
Patient Case 1: Maya, 16-Month-Old Girl With SLC26A4-Related Hearing Loss
As a genetic counselor practicing in an academic medical center, you are meeting with Maya and her family. Maya is a 16-month-old girl who was referred after her newborn hearing screening. She has confirmed bilateral moderate to severe SNHL, and her parents report that Maya responds inconsistently to speech at home despite well-fit hearing aids. Early intervention services were initiated.
There is no known family history of pediatric hearing loss. Her mom’s pregnancy and delivery were uncomplicated, and congenital cytomegalovirus testing was not completed in the newborn period. Furthermore, physical examination shows no pigmentary changes, craniofacial anomalies, renal findings, cardiac concerns, or developmental regression.
Comprehensive gene panel testing for hearing loss identifies 2 pathogenic variants in the SLC26A4 gene that are consistent with autosomal recessive SLC26A4-related hearing loss. Furthermore, SLC26A4-related hearing loss is associated with Pendred syndrome and nonsyndromic vestibular aqueduct enlargement.2 Temporal bone imaging for Maya confirms bilateral enlarged vestibular aqueducts.
Maya’s parents ask, “What does this mean for Maya’s hearing? Are there other health issues we need to watch for? Does this change whether she might need cochlear implants? And should we be looking into gene therapy?”
Interpreting Variant Classification Within Clinical Context
The American College of Medical Genetics and Genomics (ACMG) and Association of Molecular Pathology guidelines classify sequence variants into 5 distinct categories: pathogenic, likely pathogenic, benign, likely benign, and variant of uncertain significance. Variant classification according to the guidelines ensures evidence-based interpretation via population frequency, predicted effect, functional data, co-occurrence and segregation studies, case-based observations, and consistency with the known disease.3,4
For genetic counselors, the task is to use the variant classification to better inform one’s clinical interpretation. That is because pathogenic variants must not be interpreted in isolation.5 They should be evaluated in terms of the gene–disease relationship, inheritance pattern, zygosity, and phase. Further consideration should determine whether the phenotype matches the expected disease, if the genetic testing results explain patients’ presentation, and whether additional medical evaluation is indicated.
In Maya’s case, the presence of 2 pathogenic SLC26A4 variants and enlarged vestibular aqueducts on imaging supports a molecular diagnosis of SLC26A4-related hearing loss.2 That is, Maya’s genotype, inheritance pattern, and phenotype are concordant with SLC26A4-related hearing loss. Genetic counselors should use these results to guide counseling about prognosis, recurrence risk, family testing, and surveillance.
Linking Genotype to Prognosis
SLC26A4-related hearing loss is commonly diagnosed as congenital or childhood-onset SNHL, which can fluctuate or progress. As mentioned, enlarged vestibular aqueducts on imaging frequently correlate with this genetically backed diagnosis.2
In pediatric SNHL care, genetic counseling must be informed by genotype and should prepare patients’ families for possible changes in hearing over time, if applicable. In addition, genetic counselors should avoid deterministic statements about an individual child’s auditory development in the future for cases of SLC26A4-related hearing loss.
A balanced statement on Maya’s genetic testing results might look like: “These results give us a likely explanation for Maya’s hearing loss, and children with SLC26A4-related hearing loss can experience changes over time, including progressive or fluctuating hearing loss. We cannot predict Maya’s exact course with certainty, so her management plan should include close audiologic monitoring, prompt reassessment if her responses change, and ongoing review of the available intervention options.”
Of note, this approach separates what is known from what remains uncertain for Maya’s family. Her genetic testing results support a risk of progression but do not specify the exact timing or degree of future hearing loss. Although Maya’s genetic testing results do not completely clarify her prognosis, the ACMG’s clinical practice resource on hearing loss also emphasizes that an etiologic diagnosis can inform patient education, management planning, interventional eligibility, and surveillance needs.6
Cochlear Implant Evaluation and Setting Expectations
Genetic testing also can meaningfully inform cochlear implant evaluation, but it should not replace standard assessment of patient candidacy. For children with progressive or severe genetic SNHL, cochlear implant evaluation should consider their current aided hearing thresholds and speech perception, developmental and spoken language progress, and family communication goals. Further evaluation should be made in reference to patients’ imaging findings (ie, cochlear status), medical and surgical considerations, and timing of referral to the cochlear implant team.7,8
Results from large studies support the integration of genetic diagnoses into precision care for childhood-onset hearing loss to inform characterizations of severity, prognosis, and cochlear implant outcomes by genotype. Cochlear implant remains an established intervention for severe to profound SNHL, although outcomes vary by etiology and patient-specific factors.9
For Maya, her genetic diagnosis does not mean that cochlear implant is immediately required. It does, however, support proactive evaluation. Because SLC26A4-related hearing loss may progress, Maya’s family should understand that cochlear implant evaluation may become appropriate if hearing aids no longer provide adequate access to sound and language development is impacted.2
A practical statement to share with Maya’s family may include: “We should continue with optimized hearing aids and close audiologic follow-up for Maya. Because her genetic diagnosis is associated with hearing loss that may fluctuate or progress, we must monitor her access to hearing carefully. If her benefit from hearing aids becomes limited, early referral to a cochlear implant team would be appropriate rather than waiting until delays become more pronounced.”
Feedback on Question 3
Maya’s genotype and imaging findings are concordant and support a diagnosis of SLC26A4-related hearing loss, and her genetic counseling should include discussion of possible progression or fluctuation of hearing loss, close audiologic monitoring, and multidisciplinary coordination. Furthermore, a genetic-backed diagnosis informs Maya’s prognosis and management planning but does not, by itself, mandate the need for immediate cochlear implant.
Identifying Surveillance Needs for Syndromic vs Nonsyndromic Hearing Loss
A genetic SNHL diagnosis may shift your counseling strategy from focusing on hearing loss only to a broader need for surveillance. For patients with SLC26A4-related hearing loss, this change is relevant because they can develop Pendred syndrome, which is associated with thyroid enlargement or dysfunction. Of note, clinical expression in Pendred syndrome varies. Regardless, the presence of biallelic SLC26A4 pathogenic variants should prompt a discussion about the appropriate evaluation and surveillance strategy for patients, which is typically done in coordination with otolaryngology, endocrinology, and primary care.
For genetic counselors, the central issue is how to frame surveillance needs during counseling without creating unnecessary alarm among families. A useful counseling structure may follow the below outline2,10:
- Explain the reason why surveillance is being considered: “This gene can be associated with findings of inner ear malformations and, in some people, thyroid abnormalities.”
- Clarify explicitly that the surveillance strategy is precautionary, not diagnostic: “This does not mean Maya currently has thyroid disease.”
- Coordinate with the appropriate teams: “We will communicate these results to her pediatrician and otolaryngology team, so they can help determine the right monitoring plan.”
- Avoid overpromising prediction: “Genetic testing results help us know what to watch for. They do not tell us exactly which features Maya will or will not develop.”
Furthermore, the ACMG’s clinical practice resource on hearing loss supports using an etiologic diagnosis to guide management and surveillance planning when patients’ hearing loss may be part of a broader syndrome (ie, syndromic SNHL).6
Feedback on Question 4
Biallelic pathogenic SLC26A4 variants support genetic counseling on Pendred syndrome and other related features. The appropriate response for genetic counselors is not to diagnose thyroid disease without further clinical evaluation. Instead, they should ensure that syndromic implications of SLC26A4-related hearing loss are communicated and appropriate surveillance is considered. This is important because genetic counselors have a key role in framing surveillance as a proactive and genotype-informed strategy rather than alarmist.
Communicating Clinical Uncertainty to Families Appropriately
Despite having a confirmed molecular diagnosis, uncertainty remains. This presents an opportunity for genetic counselors to distinguish between high-confidence conclusions and individualized unknowns.
In Maya’s case, high-confidence elements constitute the positive results for biallelic pathogenic SLC26A4 variants that are consistent with an autosomal recessive genetic SNHL diagnosis. In addition, her genotype and imaging findings provide plausible explanations for her moderate to severe SNHL. It is likely that her parents are carriers, although genetic testing would be needed to confirm phase and support recurrence counseling. Finally, any siblings and future pregnancies may face implications depending on her parents’ carrier status.
By contrast, the uncertain or individualized elements in Maya’s case include her exact hearing trajectory, timing and degree of hearing loss progression, and aided benefit over time. Furthermore, uncertainty remains about whether cochlear implant may be indicated (and when), whether syndromic features will develop, and the potential for relevant gene therapies for this genotype in the future.
A concise counseling approach might be: “We have a strong explanation for why Maya has hearing loss, and that helps us with management planning. What we cannot predict with certainty is exactly how her hearing will change over time or if she will need a different intervention in the future. That is why we will combine her genetic testing results with close audiology follow-up and developmental monitoring with otolaryngology and other team members.”
This distinction is particularly important when providing genetic counseling in pediatric SNHL. Families often want their child’s prognosis to be definitive or deterministic: stable vs progressive, hearing aids vs cochlear implants, and syndromic vs nonsyndromic. Genetic counselors have an important role because they can help families better tolerate persistent uncertainties within applicable and concrete management planning.11,12
Balanced Discussions on Gene Therapy for Pediatric SNHL
With recent advances in gene therapy for genetic hearing loss, families may encounter increasing media coverage on these novel therapies. That is why it is critical for genetic counselors to provide accurate, current, and genotype-specific information that clarifies or corrects any prior understandings.
As of April 2026, the FDA granted accelerated approval to lunsotogene parvec-cwha, a dual adeno-associated virus vector-based gene therapy. It is indicated to treat pediatric and adult patients with severe to profound or profound SNHL associated with OTOF variant (molecularly confirmed), preserved outer hair cell function, and no prior cochlear implant.13,14
This approval is incredibly relevant to the field, but it should not be generalized to all cases of genetic hearing loss. Maya has SLC26A4-related hearing loss, not OTOF-related hearing loss. Therefore, her family should not be told that she is eligible for an approved OTOF-directed gene therapy. At the same time, genetic counselors should avoid dismissing the family’s interest in gene therapy because this is an active area of research.
A balanced statement to share with Maya’s family may include: “There has been major progress in gene therapy for specific diagnoses of genetic hearing loss; the FDA recently approved a gene therapy for OTOF-related hearing loss. Maya’s diagnosis is SLC26A4-related hearing loss, so that specific therapy would not apply to her based on genetic testing. Although the research is ongoing, Maya’s current care should continue to focus on hearing access, language development, audiologic monitoring, and appropriate surveillance.”
Note that this language validates the family’s question about gene therapy and avoids promoting therapeutic misconception.
Key Takeaways: SLC26A4-Related Hearing Loss
A confirmed genetic diagnosis in pediatric SNHL can meaningfully inform counseling and management planning, alongside phenotype, audiologic data, imaging, family goals, and multidisciplinary care input.
For Maya, the positive results for biallelic pathogenic SLC26A4 variants and enlarged vestibular aqueducts on imaging support a diagnosis of SLC26A4-related hearing loss. This informs genetic counseling about possible hearing loss fluctuation or progression, need for close audiologic monitoring, potential cochlear implant evaluation in the future, autosomal recessive recurrence risk, and consideration of thyroid-related surveillance.
Finally, discussions about gene therapy must be genotype specific. Even though the recent approval of an OTOF-directed gene therapy is a major development in managing genetic hearing loss, it does not apply broadly to all children with SNHL. Therefore, genetic counselors should remember that the most useful counseling is specific, balanced, and linked to patients’ confirmed diagnosis.